<DOC>
	<DOCNO>NCT00354172</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , natural killer cell , aldesleukin , total-body irradiation donor umbilical cord blood stem cell transplant help stop growth abnormal cell cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine , mycophenolate mofetil , methylprednisolone transplant may stop happen . PURPOSE : This clinical trial study well give fludarabine cyclophosphamide together total-body irradiation follow donor umbilical cord blood natural killer cell , aldesleukin , umbilical cord blood transplant work treat patient refractory hematologic cancer disease .</brief_summary>
	<brief_title>Donor Umbilical Cord Blood Natural Killer Cells , Aldesleukin Umbilical Cord Blood Transplant Patients With Refractory Hematologic Cancers .</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine incidence 6-month disease free survival . The primary laboratory objective measure vivo expansion umbilical cord blood ( UCB ) derive natural killer cell ( NK ) fully ablative preparative regimen . Secondary - Determine incidence transplant-related mortality 6 month NK UCB + double UCBT - Evaluate pattern chimerism NK UCB + double UCBT - Determine incidence neutrophil engraftment day 42 NK UCB + double umbilical cord blood transplantation ( UCBT ) - Determine incidence platelet engraftment 6 month NK UCB + double UCBT - Determine incidence acute graft-versus-host disease ( GVHD ) grade II-IV grade III-IV day 100 NK UCB + double UCBT - Determine incidence chronic GVHD 1 year NK UCB + double UCBT - Determine disease-free survival 1 NK UCB + double UCBT - Determine incidence relapse 1 NK UCB + double UCBT OUTLINE : This single arm , nonrandomized , open-label study . - Myeloablative conditioning regimen : Patients receive fludarabine intravenously ( IV ) 1 hour day -18 -16 cyclophosphamide intravenously ( IV ) day -18 -17 . Patients undergo total-body irradiation twice daily day -16 -13 . - Haploidentical umbilical cord blood ( UCB ) natural killer ( NK ) cell therapy aldesleukin : Patients undergo haploidentical UCB-enriched NK cell ( CD3- deplete ) infusion day -13 . Patients receive aldesleukin subcutaneously day -13 , -11 , -9 , -7 , -5 , -3 . Some patient may also receive methylprednisolone IV day -1 0 . - UCB transplantation ( UCBT ) : Patients undergo single double UCBT day 0 . Beginning day 1 , patient receive filgrastim ( G-CSF ) IV daily blood count recover . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV 2 hour 2-3 time daily begin day -1 continue day 100 , follow taper day 180 . Patients also receive mycophenolate mofetil IV orally 2-3 time daily begin day -1 continue day 30 ( 7 day engraftment ) absence acute GVHD .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Diagnosis 1 follow : Acute myeloid leukemia active leukemia ( i.e. , complete remission [ CR ] ) , define light microscopy ( bone marrow ) fail ≥ 1 round standard chemotherapy Chronic myelogenous leukemia myeloid blast crisis second chronic phase ≥ 1 course standard chemotherapy imatinib mesylate Myelodysplastic syndrome ( MDS ) myeloproliferative disorder 10 % blast ≥ 1 course standard chemotherapy Unrelated umbilical cord blood ( UCB ) donor ( ) available Each unit must 46/6 HLAA , B , DRB1 match recipient ( 2 unit utilize ) ( UCB graft ) AND 3/6 HLAA , B , DRB1 match recipient ( UCB natural killer [ NK ] cell ) Karnofsky performance status ( PS ) 80100 % ( adult patient ) Lansky PS 50100 % ( pediatric patient ) Creatinine ≤ 2.0 mg/dL ( adult patient ) OR creatinine clearance &gt; 40 mL/min ( pediatric patient ) Bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , Alkaline phosphatase ≤ 5 time upper limit normal ( ULN ) Corrected Carbon Monoxide Diffusing Capacity ( DLCO ) &gt; 50 % normal OR oxygen saturation &gt; 92 % ( pediatric patient undergo pulmonary function test ) Left ventricular ejection fraction ≥ 45 % Pregnant nursing Positive pregnancy test ( Fertile patient must use effective contraception ) History HIV infection Active infection time transplantation Active infection Aspergillus mold within past 120 day Less 6 month since prior myeloablative transplant ( ≤ 18 year old ) Prior myeloablative allotransplant autologous transplant ( &gt; 18 year old ) No prior extensive therapy include &gt; 12 month alkylator chemotherapy &gt; 6 month alkylator therapy extensive radiation ( e.g. , mantle irradiation Hodgkin 's lymphoma ) Prior radiation therapy would make patient ineligible totalbody irradiation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>